oncology technology News
-
SurgiMab will attend the 7th Annual International Congress for Fluorescence-Guided Surgery - Coral Gables, FL, 15th and 16th feb. 2020.
Françoise Cailler, CEO and Scientific Director of SurgiMab will attend this exciting congress, where world-renowned specialists will gather together during two days to discuss the latest advances in the field of Fluorescence-Guided Surgery. Sessions will cover basic concepts, the use of NIR technology for oncology, colorectal surgery and many more exciting and innovative fields. Click ...
By SurgiMab
-
Inspirata Accelerates Its Growth as a Leading Provider of AI/NLP Technology in Oncology Informatics
Inspirata Inc. and FUJIFILM Corporation signed an asset purchase agreement for Fujifilm to acquire Inspirata’s Dynamyx® digital pathology technology, employees and customers, building off the proven success of the established partnership between the companies in UK and Europe. This milestone allows the Digital Pathology business to flourish with a partner who has the breadth, depth and ...
-
Deep Lens and Ocala Oncology/Florida Cancer Affiliates Collaborate to Expand Clinical Research Program with AI-Based Trial Matching Solution
Ocala Oncology/Florida Cancer Affiliates and Deep Lens today announced that they have entered into a strategic agreement to expand the well-established clinical research program and offering to patients at the Ocala-based practice. The collaboration will leverage Deep Lens’ artificial intelligence-based clinical trial matching solution, VIPERTM, and other support services to identify the ...
-
World-Renowned Cancer Oncologist, Health Consultant and Entrepreneur Dr. Nelson Teich Added to 4D Path’s Distinguished Advisory Board
4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, is pleased to announce that Dr. Nelson Teich, MD, MBA, MSc, has joined the company’s prestigious advisory board. A world-renowned oncologist, health consultant and entrepreneur in the field of clinical oncology, Teich will act as a global ambassador for 4D Path’s cloud-based, quantitative ...
By 4D Path Inc.
-
4D Path Expands with Multiple New Hires to Support Continued Development of Company’s Pan-Cancer Diagnostic and Precision Oncology Platform
Transitioning from his role as a 4D Path advisory board member, world-renowned cancer oncologist, health consultant, and entrepreneur Dr. Teich will now serve as 4D Path’s Chief Global Strategist. Dr. Teich’s expertise in facilitating clinical research and supporting innovative, evidence-based health technologies will support 4D Path’s efforts to bring more readily accessible ...
By 4D Path Inc.
-
EsoCap holds a multidisciplinary advisory board meeting on Barrett’s esophagus
EsoCap AG organized a multidisciplinary scientific advisory board meeting with eight international experts in Barrett’s esophagus (BE) in Zurich EsoCap’s technology for the topical treatment of Barrett’s esophagus was recognized by the experts for having high potential for clinical success EsoCap’s proprietary and unique targeted application technology for the upper ...
By EsoCap AG
-
Update on Continued Research in Oncology
Abera Bioscience AB (“Company” or “Abera”) initiated research and development in immuno-oncology in 2021 with a first sub-goal to explore the potential of the company’s platform in the area and to carry out initial studies for further prioritization. In accordance with the press release regarding a private placement sent out December 23rd, in which Abera informed ...
-
Cancer Treatment is the USA: Methods, Top Clinics, Cost, Financing Options
The USA boasts better cancer survival rates than most other developed countries. This was made possible due to a number of factors. In America, much attention is paid to medical equipment. Local oncology centers are equipped with the latest technology, actively use innovative technologies and new medicines. In addition, oncology in the United States involves extensive screening and more ...
-
IMBDx to Attend Bio Health Worldwide Online 2020
IMB Dx is attending the ‘Bio Health Worldwide Online 2020’ exhibit sponsored by KOTRA and the South Korean Ministry of Trade, Industry and Energy which will be held for 12 days beginning October 19th, 2020. Over 500 companies in the fields of biotechnology, pharmaceutical, medical device, healthcare, dietary supplements, and protective supplies, as well as over 1,000 potential buyers ...
By IMB Dx, Inc.
-
Vela Diagnostics Buys Great Basin Scientific
Adds 6 FDA Approved Products on a Medium Multiplexing Platform and Microbiology Know-how Enabling our Customers to Benefit from a New Sample-to-Result Solution Cost-Efficiently in Near Patient Care Setting; adds a Manufacturing and R&D site in Salt Lake City, UT, United States. Vela Diagnostics signed an agreement to acquire Great Basin Scientific’s assets and will take over their site ...
-
Tethis’ Reconfirmed Scientific Advisory Board appoints Prof. Nicola Aceto, Ph.D as Chairman
Tethis S.p.A announced today that in the first meeting of the reconfirmed Scientific Advisory Board held today, Nicola Aceto PhD, Professor of Molecular Oncology at the Swiss Federal Institute of Technology (ETH) Zurich, has been appointed as its new chairman. Prof. Aceto is a world-renowned leader in circulating tumor cell research, and his work on CTC clusters has been published in the highest ...
By Tethis S.p.A
-
OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases
Dr. Elias Zerhouni, ModeX Chairman, former President of Global R&D at Sanofi and former NIH Director, named President and Vice Chairman of OPKO Dr. Gary Nabel, ModeX President and CEO, former Chief Scientific Officer at Sanofi and founder of NIH’s Vaccine Research Center, joins OPKO as Chief Innovation Officer and a member of OPKO’s Board of Directors Alexis Borisy, ModeX Lead ...
-
GeneCentric Therapeutics Closes $7.5 Million Series B1 Financing
Durham, N.C., Nov. 8, 2021 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the closing of an oversubscribed Series B1 financing, which raised $7.5 million. Proceeds will be used to commercialize GeneCentric’s gene signatures and accelerate the growth of its pipeline of predictive response signatures for ...
-
NeoTherma Oncology Raises $6 Million to Advance VectRx to Human Testing
NeoTherma Oncology (NTO), developer of an advanced bioelectric medical device for noninvasive treatment of serious cancers, today announced the closing of a $6 million capital raise. The financing provides the resources to conduct human testing of NTO's VectRx™ thermal oncology treatment platform, designated by FDA as a 'Breakthrough Therapy' for Pancreatic Cancer, expediting patient access ...
-
GeneCentric to Present Initial Clinicogenomic Results from the GARNER High-Risk Non-Muscle Invasive Bladder Cancer Real-World Study
Durham, NC, May 10, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today an upcoming presentation of initial results from the GARNER (Genomic Analysis of high-Risk Non-muscle invasive bladder cancer) real-world study at the 2022 American Urological Association (AUA) Annual Meeting, which is being held in New ...
-
Lifespin Announces Expansion of Laboratory Testing Capability
Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has installed additional Nuclear Magnetic Resonance (NMR) equipment which will double Lifespin’s annual laboratory testing capacity. Lifespin will now be able to scan and create the corresponding digitized, quantitative metabolic profiles involving as many as 300,000 human samples ...
-
GeneCentric Therapeutics Collaborates with Labcorp to Develop Novel RNA-Based Oncology Diagnostics
DURHAM, N.C. – October 12, 2021 — GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced a new strategic collaboration with Labcorp, a leading global life sciences company, to develop and commercialize new RNA-based gene signatures as diagnostics for people with cancer. This latest collaboration builds on the ...
-
GeneCentric Publishes New Data Comparing Predictive Immune Response Profiles in Patients Treated with Checkpoint Inhibition or IL-2
A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced its new publication in Cancer Research Communications that compares the immunogenomic response profiles to anti-PD-(L)1 ...
-
GeneCentric to Present Discovery and Initial Clinical Utility of a Novel RNA-Based Gene Signature That Predicts Treatment Response in Patients with Head and Neck Cancer
DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the upcoming oral presentation of the discovery and initial clinical utility of a novel signature that identifies patients with head and neck squamous cell carcinoma (HNSCC) that may benefit from treatment beyond typical surgical ...
-
TreeFrog Therapeutics opens technological hub in Kobe, Japan, to drive partnerships opportunities in the field of iPSC-derived cell therapies
TreeFrog Therapeutics, a French-based biotech company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the incorporation of its Japanese subsidiary (KK) TreeFrog Therapeutics Japan and the establishment of a lab in Kobe, at the Creative Lab for Innovation Kobe (CLIK). Incorporated in Bordeaux, France, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you